PSI™ Enables Cell Engineering and Therapy from Discovery to Predicting Outcome

Learn how PSI can help you discover and reveal the key potent cell subsets that correlate to in vivo outcome in cell therapy throughout discovery and development.

Unlock Resource
Download this free resource and gain access to our full resource library!

Unlock All Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.

fierce innovation award
red dot award winner
scientist award

Ensuring the continued success of engineered immune cell therapies in the fight against cancer

CAR-T cell-based immunotherapies have had remarkable success in recent years. CAR T-cell therapy was shown to lead to a 67%- 90% complete remission (CR) rate in adults and children with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) [4-8] while only 29% of adult R/R ALL patients achieved CR with chemotherapy.

In this Application Note we discuss:
  • Use Polyfunctionality and PSI to reveal synergies and mechanism with novel Combination Therapies
  • Use PSI to clearly reveal differences in bioprocessing methods for product manufacturing process optimization
  • Predict patient response to a CAR-T therapy using pre-infusion product PSI, demonstrating its potential as a biomarker for clinical outcome
2019-11-16T10:33:18-05:00